Meyer Andrew Hollman
SEC CIK 1864159 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | Chief Business Off | 83.1K | — | $4.22M | 20 | 2024-09-27 | 2026-01-02 |
Most active insiders at JANX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Meyer Andrew Hollman | Chief Business Off | — | $736.7K |
| 2 | Campbell David Alan | Pres, CEO, Dir | — | $110.8K |
| 3 | Doyle Janeen Noel | Chief Corp, Bus. Dev. Ofcr | — | $56.9K |
| 4 | Dobek Maria | VP, Accounting | — | $49.0K |
| 5 | McIver Zachariah | Chief Medical Off | — | $37.3K |
| 6 | DiRaimondo Thomas | CSO | — | $34.4K |
| 7 | Winter Charles M. | Chief Technical Off | — | $33.0K |
| 8 | Go William | Chief Medical Off | — | — |
| 9 | Simson Jake | Dir | — | — |
| 10 | Hernday Natasha | Dir | — | — |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-02 | 2026-01-02 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale | $13.73 | -1,879 | 83.1K | -2% | -$25.8K | |
| DM | 2025-12-03 | 2025-12-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $32.98 | -3,333 | 85.6K | -4% | -$109.9K |
| D | 2025-12-03 | 2025-12-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $10.59 | +3,333 | 88.3K | +4% | +$35.3K |
| D | 2025-11-14 | 2025-11-14 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $30.00 | -3,333 | 85.0K | -4% | -$100.0K |
| D | 2025-11-14 | 2025-11-14 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $10.59 | +3,333 | 88.3K | +4% | +$35.3K |
| D | 2025-10-30 | 2025-10-28 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $30.06 | -16.7K | 82.1K | -17% | -$500.9K |
| DM | 2025-10-30 | 2025-10-28 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $6.76 | +16.7K | 98.8K | +20% | +$112.7K |
| DM | 2025-05-02 | 2025-05-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $32.03 | -3,333 | 82.5K | -4% | -$106.7K |
| D | 2025-05-02 | 2025-05-01 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $4.21 | +3,333 | 85.5K | +4% | +$14.0K |
| D | 2025-04-23 | 2025-04-21 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $30.00 | -3,334 | 82.1K | -4% | -$100.0K |
| D | 2025-04-23 | 2025-04-21 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $4.21 | +3,334 | 85.5K | +4% | +$14.0K |
| D | 2025-03-05 | 2025-03-03 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $4.21 | +3,334 | 85.5K | +4% | +$14.0K |
| DM | 2025-03-05 | 2025-03-03 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $32.14 | -3,334 | 83.0K | -4% | -$107.2K |
| DM | 2025-02-05 | 2025-02-03 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $42.29 | -3,334 | 83.1K | -4% | -$141.0K |
| D | 2025-02-05 | 2025-02-03 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $4.21 | +3,334 | 85.5K | +4% | +$14.0K |
| DM | 2025-01-03 | 2025-01-02 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale | $54.88 | -13.3K | 82.1K | -14% | -$731.8K |
| D | 2025-01-03 | 2025-01-02 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | A - Grant | $0.00 | +18.0K | 95.5K | +23% | $0 |
| DM | 2024-12-20 | 2024-12-19 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $20.24 | +9,881 | 77.5K | +15% | +$200.0K |
| D | 2024-09-27 | 2024-09-27 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | S - Sale+OE | $45.96 | -50.0K | 67.6K | -43% | -$2.30M |
| D | 2024-09-27 | 2024-09-27 | JANX | Janux Therapeutics, Inc. | Meyer Andrew Hollman | Chief Business Off | M - OptEx | $4.21 | +50.0K | 117.6K | +74% | +$210.5K |
Purchase Sale Sale after option exercise All abbreviations